Correction : Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results

Affiliations

• ¹ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY, 10029, USA. george.diaz@mssm.edu.
• ² Medical Genetics Service HCPA, Department of Genetics UFRGS, DASA and Casa Dos Raros, Porto Alegre, Brazil.
• ³ Reference Centre of Inherited Metabolic Disease in Femme Mère Enfant Hospital, Hospices Civils of Lyon, Lyon, France.
• ⁴ Manchester University National Health Service Trust, St Mary's Hospital, Manchester, UK.
• ⁵ Institute of Clinical Science for Lysosomal Storage Disorders, SphinCS GmbH, Mainz, Germany.
• ⁶ University Hospital of Udine, Udine, Italy.
• ⁷ University Hospitals Leuven, Louvain, Belgium.
• ⁸ Sanofi, Bridgewater, NJ, USA.
• ⁹ Sanofi, Cambridge, MA, USA.
• ¹⁰ Sanofi, Paris, France.